Evonik Starts Strong in 2025
.jpg?1654523773)
Evonik reported higher earnings for the first quarter of 2025, citing volume gains, improved pricing in animal nutrition, and continued cost discipline. Adjusted EBITDA increased 7 percent year over year to €560 million, and free cash flow rose 53 percent to €195 million. Revenue remained stable at €3.78 billion.
“We had a good start to the year,” said Chief Executive Officer Christian Kullmann. “However, the combination of a looming global trade war and armed conflicts makes planning for the future more uncertain than ever.”
Evonik confirmed its 2025 earnings outlook of €2.0 billion to €2.3 billion in adjusted EBITDA. Net income rose to €233 million from €156 million in the prior-year quarter. The adjusted EBITDA margin increased to 14.8 percent.
The company reported strong performance in its Nutrition & Care division, where sales rose 12 percent to €1,007 million, and adjusted EBITDA increased 35 percent to €197 million. The Specialty Additives division saw a 1 percent increase in both sales and EBITDA, supported by higher demand from the coatings and crosslinkers markets. Smart Materials remained stable in sales but reported a 7 percent decline in EBITDA due to the absence of licensing income.
Evonik cited internal efficiency efforts and restructuring—including the elimination of division-level management and a leaner corporate structure—as key to maintaining its strategic direction.
Learn more details here.
Looking for a reprint of this article?
From high-res PDFs to custom plaques, order your copy today!